Meenakshi Hegde

Meenakshi Hegde

Auto-generated profile, based on publicly available information

Meenakshi Hegde

Baylor College of Medicine, Houston, Texas, United States

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2016 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
MHMeenakshi Hegde
Meenakshi Hegde
MMMalini Mukherjee
Malini Mukherjee
ZGZakaria Grada
Zakaria Grada
APAntonella Pignata
Antonella Pignata
DLDaniel Landi
Daniel Landi
NANabil Ahmed
Nabil Ahmed
In preclinical models of glioblastoma, antigen escape variants can lead to tumor recurrence after treatment with CAR T cells that are redirected to single tumor antigens. Given the heterogeneous expression of antigens on glioblastomas, we hypothesized that a bispecific CAR molecule would mitigate antigen escape and improve the antitumor activity of T cells. Here, we created a CAR that joins a HER2-binding scFv and an IL13Rα2-binding IL-13 mutein to make a tandem CAR exodomain (TanCAR) and a CD28.ζ endodomain. We determined that patient TanCAR T cells showed distinct binding to HER2 or IL13Rα2 and had the capability to lyse autologous glioblastoma. TanCAR T cells exhibited activation dynamics that were comparable to those of single CAR T cells upon encounter of HER2 or IL13Rα2. We observed that TanCARs engaged HER2 and IL13Rα2 simultaneously by inducing HER2-IL13Rα2 heterodimers, which promoted superadditive T cell activation when both antigens were encountered concurrently. TanCAR T cell activity was more sustained but not more exhaustible than that of T cells that coexpressed a HER2 CAR and an IL13Rα2 CAR, T cells with a unispecific CAR, or a pooled product. In a murine glioblastoma model, TanCAR T cells mitigated antigen escape, displayed enhanced antitumor efficacy, and improved animal survival. Thus, TanCAR T cells show therapeutic potential to improve glioblastoma control by coengaging HER2 and IL13Rα2 in an augmented, bivalent immune synapse that enhances T cell functionality and reduces antigen escape.

1 November 2013 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
MHMeenakshi Hegde
Meenakshi Hegde
ACAmanda Corder
Amanda Corder
KCKevin Kh Chow
Kevin Kh Chow
MMMalini Mukherjee
Malini Mukherjee
AAAidin Ashoori
Aidin Ashoori
NANabil Ahmed
Nabil Ahmed
Preclinical and early clinical studies have demonstrated that chimeric antigen receptor (CAR)-redirected T cells are highly promising in cancer therapy. We observed that targeting HER2 in a glioblastoma (GBM) cell line results in the emergence of HER2-null tumor cells that maintain the expression of nontargeted tumor-associated antigens. Combinational targeting of these tumor-associated antigens could therefore offset this escape mechanism. We studied the single-cell coexpression patterns of HER2, IL-13Rα2, and EphA2 in primary GBM samples using multicolor flow cytometry and immunofluorescence, and applied a binomial routine to the permutations of antigen expression and the related odds of complete tumor elimination. This mathematical model demonstrated that cotargeting HER2 and IL-13Rα2 could maximally expand the therapeutic reach of the T cell product in all primary tumors studied. Targeting a third antigen did not predict an added advantage in the tumor cohort studied. We therefore generated bispecific T cell products from healthy donors and from GBM patients by pooling T cells individually expressing HER2 and IL-13Rα2-specific CARs and by making individual T cells to coexpress both molecules. Both HER2/IL-13Rα2-bispecific T cell products offset antigen escape, producing enhanced effector activity in vitro immunoassays (against autologous glioma cells in the case of GBM patient products) and in an orthotopic xenogeneic murine model. Further, T cells coexpressing HER2 and IL-13Rα2-CARs exhibited accentuated yet antigen-dependent downstream signaling and a particularly enhanced antitumor activity.

15 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
MHMeenakshi Hegde
Meenakshi Hegde
SJSujith K. Joseph
Sujith K. Joseph
FPFarzana Pashankar
Farzana Pashankar
CDChristopher DeRenzo
Christopher DeRenzo
KSKhaled Sanber
Khaled Sanber
NANabil Ahmed
Nabil Ahmed
Refractory metastatic rhabdomyosarcoma is largely incurable. Here we analyze the response of a child with refractory bone marrow metastatic rhabdomyosarcoma to autologous HER2 CAR T cells. Three cycles of HER2 CAR T cells given after lymphodepleting chemotherapy induces remission which is consolidated with four more CAR T-cell infusions without lymphodepletion. Longitudinal immune-monitoring reveals remodeling of the T-cell receptor repertoire with immunodominant clones and serum autoantibodies reactive to oncogenic signaling pathway proteins. The disease relapses in the bone marrow at six months off-therapy. A second remission is achieved after one cycle of lymphodepletion and HER2 CAR T cells. Response consolidation with additional CAR T-cell infusions includes pembrolizumab to improve their efficacy. The patient described here is a participant in an ongoing phase I trial (NCT00902044; active, not recruiting), and is 20 months off T-cell infusions with no detectable disease at the time of this report.

24 April 2024 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
MHMeenakshi Hegde
Meenakshi Hegde
SNShoba Navai
Shoba Navai
CDChristopher DeRenzo
Christopher DeRenzo
SJSujith K. Joseph
Sujith K. Joseph
KSKhaled Sanber
Khaled Sanber
NANabil Ahmed
Nabil Ahmed

7 July 2022 in Blood
Verified
Journal Article
Open access
PDF file
DSDavid H. M. Steffin
David H. M. Steffin
IMIbrahim N. Muhsen
Ibrahim N. Muhsen
LHLaQuisa Hill
LaQuisa Hill
CRCarlos A. Ramos
Carlos A. Ramos
NANabil Ahmed
Nabil Ahmed
HHHelen E. Heslop
Helen E. Heslop
Subsequent malignancies are well-documented complications in long-term follow-up of cancer patients. Recently, genetically modified immune effector (IE) cells have shown benefit in hematologic malignancies and are being evaluated in clinical trials for solid tumors. Although the short-term complications of IE cells are well described, there is limited literature summarizing long-term follow-up, including subsequent malignancies. We retrospectively reviewed data from 340 patients treated across 27 investigator-initiated pediatric and adult clinical trials at our center. All patients received IE cells genetically modified with γ-retroviral vectors to treat relapsed and/or refractory hematologic or solid malignancies. In a cumulative 1027 years of long-term follow-up, 13 patients (3.8%) developed another cancer with a total of 16 events (4 hematologic malignancies and 12 solid tumors). The 5-year cumulative incidence of a first subsequent malignancy in the recipients of genetically modified IE cells was 3.6% (95% confidence interval, 1.8% to 6.4%). For 11 of the 16 subsequent tumors, biopsies were available, and no sample was transgene positive by polymerase chain reaction. Replication-competent retrovirus testing of peripheral blood mononuclear cells was negative in the 13 patients with subsequent malignancies tested. Rates of subsequent malignancy were low and comparable to standard chemotherapy. These results suggest that the administration of IE cells genetically modified with γ retroviral vectors does not increase the risk for subsequent malignancy.

2 July 2019 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MHMeenakshi Hegde
Meenakshi Hegde
MMMalini Mukherjee
Malini Mukherjee
ZGZakaria Grada
Zakaria Grada
APAntonella Pignata
Antonella Pignata
DLDaniel Landi
Daniel Landi
NANabil Ahmed
Nabil Ahmed